23andMe: 23andMe Launches Discover23 to Help Accelerate Large-Scale Genetics Research for Biopharma Collaborators, Powered by Lifebit?s Trusted Technology

23andMe Holding Co. announced the launch of Discover23®, a new research offering enabling authorized collaborators to securely access the power and diversity of the 23andMe research cohort through a Trusted Research Environment (TRE) developed by Lifebit, a technology company trusted by some of the world?s leading biomedical research organizations and governments. Discover23 provides analysis-ready genome-wide association studies (GWAS) conducted on 1000+ disease and condition cohorts curated from 4.7B phenotypic data points by 23andMe?s expert scientists. Biopharma collaborators will be able to access summarized results of analyses conducted using data stripped of personal identifiers within 23andMe?s TRE, where authorized researchers are provided with highly secure, isolated workspaces to leverage 23andMe research findings while ensuring the protection of participant privacy. Discover23 evaluates associations of over 172 million genetic variants across billions of phenotypic data points provided by consenting 23andMe research participants. Approximately 84% of the Company?s 15 million customers have opted in to participate in 23andMe?s Research program. Partners can use Discover23 to help identify novel disease biology, discover potential new drug targets, and add genetic evidence into research programs to boost clinical success. 23andMe Holding Co. announced the launch of Discover23®, a new research offering enabling authorized collaborators to securely access the power and diversity of the 23andMe research cohort through a Trusted Research Environment (TRE) developed by Lifebit, a technology company trusted by some of the world?s leading biomedical research organizations and governments. Discover23 provides analysis-ready genome-wide association studies (GWAS) conducted on 1000+ disease and condition cohorts curated from 4.7B phenotypic data points by 23andMe?s expert scientists. Biopharma collaborators will be able to access summarized results of analyses conducted using data stripped of personal identifiers within 23andMe?s TRE, where authorized researchers are provided with highly secure, isolated workspaces to leverage 23andMe research findings while ensuring the protection of participant privacy. Discover23 evaluates associations of over 172 million genetic variants across billions of phenotypic data points provided by consenting 23andMe research participants. Approximately 84% of the Company?s 15 million customers have opted in to participate in 23andMe?s Research program. Partners can use Discover23 to help identify novel disease biology, discover potential new drug targets, and add genetic evidence into research programs to boost clinical success.